Startup · $3m raised
Programs: Brandon BioCatalyst (CUREator+) · CUREator+ (CUREator+) · Brandon BioCatalyst (CUREator)
Every investor coverage indicates participated in a round Frontier Inflammasome Therapeutics raised.
| Investor | Rounds | Invested |
|---|---|---|
| CUREator+ | Accelerator · Grant | - |
| Brandon BioCatalyst | Accelerator · Grant · Grant | - |
Companies Frontier Inflammasome Therapeutics acquired or merged with, per published coverage. Buying a company is not investing in one: nothing here counts in the deals column.
Stories naming Frontier Inflammasome Therapeutics. Where several outlets covered the same round, they are bundled under whichever ran the fullest account.
Six Australian health tech startups received non-dilutive grants totaling $13.5 million from the government-backed CUREator+ program to accelerate commercialisation of medical innovations.
Six Australian biomedical and health ventures receive a combined $13.5 million in non-dilutive grants through round two of the CUREator+ commercialisation program operated by Brandon BioCatalyst and backed by the Medical Research Future Fund.
Also Dealroom
Six Australian health tech startups received a combined $13.5 million in non-dilutive funding from the CUREator+ program, supported by the Australian Government.
CUREator+ granted thirteen point five million dollars in non-dilutive funding to six Australian health tech startups to support commercialisation of medical innovations.
CUREator, Brandon BioCatalyst's government-backed grant program, has awarded $7.21 million across eight Australian biotech firms in its newest round, split between clinical-stage and preclinical recipients.
Also Brandon BioCatalyst portfolio·Startup Daily·ausceleratesa.org
Brandon BioCatalyst's CUREator incubator names its first-round awardees, distributing government-backed funding across 23 Australian life science companies working on treatments from schizophrenia to diabetes, with round two applications now open.
The CUREator incubator, run by Brandon BioCatalist's partner organisation, names its first-round awardees, distributing government-backed grant funding across 23 Australian life science companies developing treatments for diseases including diabetes, cancer and COPD.